Vital Therapies Appoints Former Receptos President and CEO Faheem Hasnain as Chairman of the Board of Directors
06 sept. 2017 08h01 HE
|
Vital Therapies, Inc.
SAN DIEGO, Sept. 06, 2017 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver...
Vital Therapies Announces Second Quarter 2017 Financial Results
03 août 2017 16h01 HE
|
Vital Therapies, Inc.
SAN DIEGO, Aug. 03, 2017 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver...
Vital Therapies Announces Upcoming Second Quarter Financial Results Conference Call With Webcast
26 juil. 2017 16h01 HE
|
Vital Therapies, Inc.
SAN DIEGO, July 26, 2017 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver...
Vital Therapies Announces Characteristics of Early Subjects in VTL-308 Pivotal Study of ELAD System in Severe Alcoholic Hepatitis
05 juin 2017 08h01 HE
|
Vital Therapies, Inc.
SAN DIEGO, June 05, 2017 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver...
Vital Therapies Announces First Quarter 2017 Financial Results
09 mai 2017 16h01 HE
|
Vital Therapies, Inc.
SAN DIEGO, May 09, 2017 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver...
Vital Therapies Announces Upcoming First Quarter Financial Results Conference Call With Webcast
02 mai 2017 16h01 HE
|
Vital Therapies, Inc.
SAN DIEGO, May 02, 2017 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver...
Vital Therapies Announces Exercise in Full of Underwriters’ Option to Purchase Additional Shares of Common Stock in Public Offering
29 mars 2017 16h01 HE
|
Vital Therapies, Inc.
SAN DIEGO, March 29, 2017 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver...
Vital Therapies Announces Pricing of Public Offering of Common Stock
22 mars 2017 09h06 HE
|
Vital Therapies, Inc.
SAN DIEGO, March 22, 2017 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver...
Vital Therapies Announces Proposed Public Offering of Common Stock
21 mars 2017 16h01 HE
|
Vital Therapies, Inc.
SAN DIEGO, March 21, 2017 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing the ELAD® System, a cell-based therapy targeting the treatment of liver failure,...
Vital Therapies Announces Fourth Quarter and Full Year 2016 Financial Results
07 mars 2017 16h01 HE
|
Vital Therapies, Inc.
SAN DIEGO, March 07, 2017 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver...